David A Scott

This inventor holds 15 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignees: Dana-Farber-Cancer Institute Inc., Children's Medical Center Corporation, Cornell University. Active years: 2020-2026.

USPTO Granted Patents = 15 (Patent Applications = 5)

% Patents Active = 93.3

EPO Patents = 3 (Patent Applications = 12)

Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Newton, MA (US) (2020 - 2023)
Boston, MA (US) (2021 - 2024)

Company Filing History:

14 out of 1,264

Dana-Farber-Cancer Institute Inc.

patents

4 out of 1,071

Children's Medical Center Corporation

The Schepens Eye Research Institute, Inc.

patents

where one patent can have more than one assignee

Years Active: 2020-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12622909 - Allosteric EGFR inhibitors and methods of use thereof (2026-05-12),

2. 12391671 - Allosteric EGFR inhibitors and methods of use thereof (2025-08-19),

3. 12377080 - Allosteric EGFR inhibitors and methods of use thereof (2025-08-05),

4. 12365696 - Small-molecule focal adhesion kinase (FAK) inhibitors (2025-07-22),

5. 12318452 - Degraders of WEE1 kinase (2025-06-03),

6. 12268739 - Use of toll-like receptor 2 (TLR-2) agonist for modulating human immune response (2025-04-08),

7. 12161649 - Inhibitors of EGFR and methods of use thereof (2024-12-10),

8. 11945816 - Inhibitors of EGFR and/or HER2 and methods of use (2024-04-02),

9. 11730810 - Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response (2023-08-22),

10. 11673891 - Imidazopyrimidine compounds and uses thereof (2023-06-13),

11. 11260048 - Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same (2022-03-01),

12. 11248007 - Inhibitors of MALT1 and uses thereof (2022-02-15),

13. 11186574 - Inhibitors of EGFR and/or HER2 and methods of use (2021-11-30),

14. 10711036 - MALT1 inhibitors and uses thereof (2020-07-14),

15. 10689366 - Compounds for MALT1 degredation (2020-06-23),

Title: Exploring the Innovations of David A Scott: Pioneering Inventor in Newton, MA

Introduction:

David A Scott, a prominent inventor hailing from Newton, MA, has left an indelible mark in the field of medical advancements with his innovative patents and groundbreaking research.

Latest Patents:

1. "Inhibitors of EGFR and/or HER2 and methods of use": This patent showcases a compound that modulates the activity of HER2 and/or EGFR, paving the way for novel methods of treating diseases where these proteins play a crucial role.

2. "Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response": Scott's work on imidazopyrimidine compounds aims to enhance human immune responses and serve as adjuvants in vaccines, revolutionizing the field of immunotherapy.

Career Highlights:

With a remarkable portfolio of 8 patents, David A Scott has demonstrated his prowess in developing cutting-edge solutions for complex medical challenges. His contributions have significantly impacted the realms of oncology, immunology, and drug development.

Collaborations:

Throughout his career, Scott has collaborated with esteemed professionals such as John M Hatcher and Nathanael Schiander Gray. His time at Dana-Farber Cancer Institute Inc. and Cornell University has further enriched his research endeavors, fostering a culture of innovation and collaboration.

Conclusion:

David A Scott's dedication to innovation and penchant for pushing the boundaries of scientific discovery make him a standout figure in the world of inventors. His patents not only reflect his expertise but also underscore his commitment to improving healthcare practices and enhancing human well-being.